64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

64Cu-DOTATATE PET for Neuroendocrine Tumors : A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. / Pfeifer, Andreas; Knigge, Ulrich; Binderup, Tina; Mortensen, Jann; Oturai, Peter; Loft, Annika; Berthelsen, Anne Kiil; Langer, Seppo W; Rasmussen, Palle; Elema, Dennis; von Benzon, Eric; Højgaard, Liselotte; Kjaer, Andreas.

In: Journal of Nuclear Medicine, Vol. 56, No. 6, 06.2015, p. 847-54.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Pfeifer, A, Knigge, U, Binderup, T, Mortensen, J, Oturai, P, Loft, A, Berthelsen, AK, Langer, SW, Rasmussen, P, Elema, D, von Benzon, E, Højgaard, L & Kjaer, A 2015, '64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients', Journal of Nuclear Medicine, vol. 56, no. 6, pp. 847-54. https://doi.org/10.2967/jnumed.115.156539

APA

Pfeifer, A., Knigge, U., Binderup, T., Mortensen, J., Oturai, P., Loft, A., ... Kjaer, A. (2015). 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. Journal of Nuclear Medicine, 56(6), 847-54. https://doi.org/10.2967/jnumed.115.156539

Vancouver

Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A et al. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. Journal of Nuclear Medicine. 2015 Jun;56(6):847-54. https://doi.org/10.2967/jnumed.115.156539

Author

Pfeifer, Andreas ; Knigge, Ulrich ; Binderup, Tina ; Mortensen, Jann ; Oturai, Peter ; Loft, Annika ; Berthelsen, Anne Kiil ; Langer, Seppo W ; Rasmussen, Palle ; Elema, Dennis ; von Benzon, Eric ; Højgaard, Liselotte ; Kjaer, Andreas. / 64Cu-DOTATATE PET for Neuroendocrine Tumors : A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. In: Journal of Nuclear Medicine. 2015 ; Vol. 56, No. 6. pp. 847-54.

Bibtex

@article{9c975885f0394477ae47364b6cba7f3f,
title = "64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients",
abstract = "Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs. We have previously shown the clinical potential of (64)Cu-DOTATATE in a small first-in-human feasibility study. The aim of the present study was, in a larger prospective design, to compare on a head-to-head basis the performance of (64)Cu-DOTATATE and (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as a routine.METHODS: We prospectively enrolled 112 patients with pathologically confirmed NETs of gastroenteropancreatic or pulmonary origin. All patients underwent both PET/CT with (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d. PET scans were acquired 1 h after injection of 202 MBq (range, 183-232 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan. Patients were followed for 42-60 mo for evaluation of discrepant imaging findings. The McNemar test was used to compare the diagnostic performance.RESULTS: Eighty-seven patients were congruently PET- and SPECT-positive. No SPECT-positive cases were PET-negative, whereas 10 false-negative SPECT cases were identified using PET. The diagnostic sensitivity and accuracy of (64)Cu-DOTATATE (97{\%} for both) were significantly better than those of (111)In-DTPA-OC (87{\%} and 88{\%}, respectively, P = 0.017). In 84 patients (75{\%}), (64)Cu-DOTATATE identified more lesions than (111)In-DTPA-OC and always at least as many. In total, twice as many lesions were detected with (64)Cu-DOTATATE than with (111)In-DTPA-OC. Moreover, in 40 of 112 cases (36{\%}) lesions were detected by (64)Cu-DOTATATE in organs not identified as disease-involved by (111)In-DTPA-OC.CONCLUSION: With these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients. Therefore, we do not hesitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.",
keywords = "Adult, Aged, Aged, 80 and over, Biopsy, Female, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Multimodal Imaging, Neoplasm Metastasis, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Pentetic Acid, Positron-Emission Tomography, Prospective Studies, Receptors, Somatostatin, Stomach Neoplasms, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed",
author = "Andreas Pfeifer and Ulrich Knigge and Tina Binderup and Jann Mortensen and Peter Oturai and Annika Loft and Berthelsen, {Anne Kiil} and Langer, {Seppo W} and Palle Rasmussen and Dennis Elema and {von Benzon}, Eric and Liselotte H{\o}jgaard and Andreas Kjaer",
note = "{\circledC} 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2015",
month = "6",
doi = "10.2967/jnumed.115.156539",
language = "English",
volume = "56",
pages = "847--54",
journal = "The Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "6",

}

RIS

TY - JOUR

T1 - 64Cu-DOTATATE PET for Neuroendocrine Tumors

T2 - A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients

AU - Pfeifer, Andreas

AU - Knigge, Ulrich

AU - Binderup, Tina

AU - Mortensen, Jann

AU - Oturai, Peter

AU - Loft, Annika

AU - Berthelsen, Anne Kiil

AU - Langer, Seppo W

AU - Rasmussen, Palle

AU - Elema, Dennis

AU - von Benzon, Eric

AU - Højgaard, Liselotte

AU - Kjaer, Andreas

N1 - © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2015/6

Y1 - 2015/6

N2 - Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs. We have previously shown the clinical potential of (64)Cu-DOTATATE in a small first-in-human feasibility study. The aim of the present study was, in a larger prospective design, to compare on a head-to-head basis the performance of (64)Cu-DOTATATE and (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as a routine.METHODS: We prospectively enrolled 112 patients with pathologically confirmed NETs of gastroenteropancreatic or pulmonary origin. All patients underwent both PET/CT with (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d. PET scans were acquired 1 h after injection of 202 MBq (range, 183-232 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan. Patients were followed for 42-60 mo for evaluation of discrepant imaging findings. The McNemar test was used to compare the diagnostic performance.RESULTS: Eighty-seven patients were congruently PET- and SPECT-positive. No SPECT-positive cases were PET-negative, whereas 10 false-negative SPECT cases were identified using PET. The diagnostic sensitivity and accuracy of (64)Cu-DOTATATE (97% for both) were significantly better than those of (111)In-DTPA-OC (87% and 88%, respectively, P = 0.017). In 84 patients (75%), (64)Cu-DOTATATE identified more lesions than (111)In-DTPA-OC and always at least as many. In total, twice as many lesions were detected with (64)Cu-DOTATATE than with (111)In-DTPA-OC. Moreover, in 40 of 112 cases (36%) lesions were detected by (64)Cu-DOTATATE in organs not identified as disease-involved by (111)In-DTPA-OC.CONCLUSION: With these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients. Therefore, we do not hesitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.

AB - Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs. We have previously shown the clinical potential of (64)Cu-DOTATATE in a small first-in-human feasibility study. The aim of the present study was, in a larger prospective design, to compare on a head-to-head basis the performance of (64)Cu-DOTATATE and (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as a routine.METHODS: We prospectively enrolled 112 patients with pathologically confirmed NETs of gastroenteropancreatic or pulmonary origin. All patients underwent both PET/CT with (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d. PET scans were acquired 1 h after injection of 202 MBq (range, 183-232 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan. Patients were followed for 42-60 mo for evaluation of discrepant imaging findings. The McNemar test was used to compare the diagnostic performance.RESULTS: Eighty-seven patients were congruently PET- and SPECT-positive. No SPECT-positive cases were PET-negative, whereas 10 false-negative SPECT cases were identified using PET. The diagnostic sensitivity and accuracy of (64)Cu-DOTATATE (97% for both) were significantly better than those of (111)In-DTPA-OC (87% and 88%, respectively, P = 0.017). In 84 patients (75%), (64)Cu-DOTATATE identified more lesions than (111)In-DTPA-OC and always at least as many. In total, twice as many lesions were detected with (64)Cu-DOTATATE than with (111)In-DTPA-OC. Moreover, in 40 of 112 cases (36%) lesions were detected by (64)Cu-DOTATATE in organs not identified as disease-involved by (111)In-DTPA-OC.CONCLUSION: With these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients. Therefore, we do not hesitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biopsy

KW - Female

KW - Humans

KW - Image Processing, Computer-Assisted

KW - Male

KW - Middle Aged

KW - Multimodal Imaging

KW - Neoplasm Metastasis

KW - Neuroendocrine Tumors

KW - Octreotide

KW - Organometallic Compounds

KW - Pentetic Acid

KW - Positron-Emission Tomography

KW - Prospective Studies

KW - Receptors, Somatostatin

KW - Stomach Neoplasms

KW - Tomography, Emission-Computed, Single-Photon

KW - Tomography, X-Ray Computed

U2 - 10.2967/jnumed.115.156539

DO - 10.2967/jnumed.115.156539

M3 - Journal article

C2 - 25952736

VL - 56

SP - 847

EP - 854

JO - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -

ID: 160404738